According to CDMO GenScript ProBio, the company has signed an agreement with Thai company Hibiocy for manufacturing of Covitrap, an intranasal antibody cocktail for the prevention of COVID-19. GenScript said that the deal includes both clinical trial and commercial manufacturing of Covitrap, as well as work on development of new products. The company said that
Manufacturing of the nasal spray, which was developed by Hibiocy in conjunction with Chulalongkorn University, Silpakorn University, the Health Systems Research Institute, and the Thai Government Pharmaceutical Organization, was recently approved by the Thai FDA and will be marketed in Thailand as “Vaill CoviTRAP Anti-CoV nasal spray.” GenScript reports that Hibiocy intends to develop the nasal spray for other countries as well.
Hibiocy CEO Worrawan Chaikamnerd commented, “This collaboration with GenScript in this ground-breaking discovery behind the development of innovative respiratory-care medical device with human antibody for inhibiting Covid-19 is critical given the growing concern of Covid-19 impacting daily life as well as unknown long Covid-19 impacts and more uncertain conditions from infections. We believe this discovery and collaboration with GenScript will bring global innovative solution with a bright opportunity for us to protect and save more lives from either getting infected or reinfected from new variances of Covid-19. In the end, this life changing solution will bring back a normal life for everyone.”
GenScript Asia Pacific President Johnson Wang responded, “At GenScript, we are resolute in our commitment to advancing human health as part of our mission to save and improve lives. We believe the Covid-19 nasal spray device represents a promising approach to combating the novel coronavirus pandemic and will bring benefit to the public. This collaboration with Hibiocy brings together two companies dedicated to the fight against Covid-19 to utilize our joint capabilities in complementary and synergistic ways to address this difficult global health challenge.”
Read the GenScript press release.
